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Adherence to imatinib mesylate improves clinical outcomes and promotes a reduction in health 
expenditure. However, treatment duration and lack of efficacy decrease adherence to pharmacotherapy, 
resulting in increased mortality associated with Chronic Myeloid Leukemia. This study aimed to 
evaluate and compare adherence and/or discontinuation of imatinib mesylate in different studies from 
the literature. An integrative review of original articles published between the years of 2004 and 2014 
was performed using the databases PubMed/MEDLINE, Scopus and SciELO. The descriptor “imatinib” 
was used in two combinations employing the connector AND between terms: “medication adherence’’ 
AND ‘’imatinib” AND “leukemia’’ and ‘’patient compliance’’ AND “imatinib” AND “leukemia”. 
We identified 476 studies, being 14 included in the study. The rates of adherence and discontinuation 
were diverse, ranging from 19.0 to 97.0% and from 1.8 and 41.0%, respectively, and a high number of 
longitudinal studies was observed (71.4%). Most studies used questionnaires as an indirect method to 
assess adherence and factors related to poor adherence were adverse drug reactions, dose changes and 
unavailability of the medication. Patient education associated with follow up by pharmacists and other 
health professionals can improve patient adherence and minimize the pharmacotherapy discontinuation.
Uniterms: Chronic Myeloid Leukemia/treatment. Imatinib Mesylate/treatment adherence. Medication 
adherence. Pharmacotheraphy review.
INTRODUCTION
Chronic myeloid leukemia (CML) represents 7 to 
20% of all hematologic neoplasias, with an incidence 
between one and two cases per 100,000 individuals per 
year (Mauro et al., 2015). Its frequency is higher among 
adults aging between 55 to 60 years old and rare during 
childhood, accounting for only 3% of all the cases of CML 
(Tefferi et al., 2005; Suttorp, Millot, 2010). It affects both 
sexes, with a slight predominance in males in a ratio of 2.2 
men for 1.4 women affected (Berger et al., 2005).
CML is characterized by a clonal myeloproliferative 
neoplasia of cells of the granulocyte lineage, which retains 
the abilities of maturation and differentiation (Perrotti 
et al., 2010). It is associated with a specific cytogenetic 
mutation on chromosome “Philadelphia” (Ph) which is a 
cytogenetic marker of CML resulting from a reciprocal 
translocation between the long arms of chromosomes 9 
and 22 containing the hybrid gene BCR/ABL. The coding 
of this gene is characterized by an enzyme with high 
tyrosine kinase activity responsible for the uncompensated 
cell proliferation, producing favorable conditions to 
the establishment of neoplastic process (Hehlmann, 
Hochhaus, Baccarani, 2007; Marin et al., 2010; Perrotti 
et al., 2010). Clinically, the stages of the disease are 
differentiated according to their evolution, being divided 
into chronic, accelerated and blast crisis or acute phases. In 
the acute phase, survival rates decrease drastically (Cortes, 
Kantarjian, 2012).
The therapeutic arsenal of CML comprises 
chemotherapeutic agents like busulfan and hydroxyurea, 
the immunobiological agent interferon α, hematopoietic 
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stem cells transplantation which is the only curative 
treatment and tyrosine kinase inhibitors represented by 
first generation drugs such as imatinib mesylate and 
second generation drugs such as nilotinib and dasatinib. 
Used since 2001, imatinib has become the first-line therapy 
in clinical protocol of CML due to some advantages 
such as low toxicity, oral administration and significant 
improvements in survival rates of patients undergoing 
treatment (85%). Imatinib use during the chronic phase 
of the disease is able to provide complete hematologic 
response rates (CHR), complete cytogenetic remission 
(CCR) and complete molecular remission (CMR) higher 
than 90% (Cortes, Kantarjian, 2012; Chen et al., 2014; 
Anderson et al., 2015).
Adherence to treatment with tyrosine kinase 
inhibitors results in improved clinical outcomes and 
promotes reduction in health costs. However, some patients 
present poor adherence to tyrosine kinase inhibitors 
impairing the responses to the treatment (Noens et al., 
2009; Hirji et al., 2013). Adherence to pharmacotherapy 
is the adequate compliance with the treatment regimen 
proposed by the doctor or other health care provider and is 
related to demographic and social conditions of the patient 
and to characteristics of the disease and the treatment 
(WHO, 2003). Intentional factors (lack of knowledge 
of the disease, travel, lack of efficacy) and unintentional 
(duration of treatment, adverse effects, unavailability 
in health services, forgetfulness, financial difficulties) 
can sometimes have an impact on patient adherence to 
treatment with imatinib mesylate, resulting in an increase 
in the mortality rate associated with the progression of 
CML (Noens et al., 2009; Eliasson et al., 2011).
One of the consequences related to non-adherence to 
imatinib is associated with resistance or intolerance to the 
drug. In this situation, many patients respond to tyrosine 
kinase inhibitors of second generation such as dasatinib 
and nilotinib, which are more potent drugs than imatinib 
and can improve the quality of life of patients with this 
clinical condition (Jabbour et al., 2012a; Bhamidipati et 
al., 2013). However, the survival rate of patients with CML 
adherent to imatinib is 16.9% higher compared to non-
adherent patients. Non-adherence and/or discontinuation 
to imatinib reduces the possibility of CCR in 18% of 
CML cases (Ganesan et al., 2011). Thus, the adherence 
to imatinib can prevent complications or exacerbations 
of CML caused by treatment failures, which would result 
in hospitalizations and procedures related to increases in 
health care costs (Halpern et al., 2009; Cid et al., 2013).
Since adherence to imatinib is crucial for successful 
treatment of patients with CML, its evaluation is necessary.
It can be performed by direct methods such as detection 
of drug or metabolite in biological fluids, addition of a 
biological marker and direct observation of the patient 
and/or indirect methods, which are simple and easy to 
perform such as patient diary, questionnaires, drug records, 
frequency of medication withdrawal in pharmacies, 
electronic monitoring of medication and manual pill count 
(Jabbour et al., 2012a; Pérez-Escamilla et al., 2015). 
Aim of the review
This review was developed in order to evaluate 
and compare adherence and/or discontinuation rates to 
imatinib mesylate in patients with CML in different studies 
found in scientific literature.
METHODS
An integrative review was performed with original 
articles published in scientific literature from 2004 to 
2014. This type of evaluation allows to incorporate 
studies with different methods, such as experimental and 
non-experimental studies, while the systematic review is 
primarily focused on experimental studies. 
Search Strategy
The articles were searched in the PubMed/
MEDLINE, Scopus and SciELO databases. The 
Medical Subject Heading (MeSH) was used to define 
the descriptors. The descriptor “imatinib” was used 
in two combinations with the descriptors “medication 
adherence”, “leukemia” and “patient compliance” using 
the connector AND between the terms: ‘’medication 
adherence’’ AND ‘’imatinib’’ AND ‘’leukemia’’ and 
‘’patient compliance’’ AND “imatinib” AND “leukemia”. 
The limits established to the search were publications 
between January 1st, 2004 and December 31st, 2014 and 
in English, Spanish and Portuguese languages. 
Inclusion and exclusion criteria
In the first phase, the articles were identified using 
the search criteria and all the duplicate records were 
deleted.
In the second stage, a prior reading of the title and 
abstract of the selected articles was performed in order to 
include only original articles, which their main objective 
was to assess adherence rates and/or discontinuation of 
imatinib in patients with CML. Review articles, notes, 
correspondence, editorial and letter were excluded. In the 
last step, articles were excluded if they did not analyze 
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the rates of adherence and/or discontinuation of imatinib. 
Original articles that addressed the issue of adherence 
were read in their entirety, in order to assess whether they 
should be included or not in the study.
Data analysis
Selected articles were subjected to a full analytical 
reading to identify the variables of interest: authorship, 
population size, age, disease stage, follow-up, study 
design, methods used to assess adherence and/or 
discontinuation, adherence and/or discontinuation rates 
and predictors related to poor adherence.
The collected data were gathered into a table 
for further analysis and interpretation. In case of any 
disagreement, a third researcher was consulted to establish 
a final agreement on the variable to be collected.
RESULTS AND DISCUSSION
We identified 476 articles through database search. 
Fourteen articles were included in the study according to 
the selection criteria (Figure 1).
The studies in accordance with the inclusion criteria 
were published in English (n = 13) and Spanish (n = 1). The 
age range of the patients included in the evaluated studies 
ranged from 13 to 89 years. Chronic myeloid leukemia 
can occur in all age groups as observed in this study, 
but it is more common in adults and rare in childhood. 
However, no conclusive evidence suggests that age may 
be a factor involved in adherence to imatinib (Reis et al., 
2013; Efficace et al., 2014). Some studies suggest higher 
adherence rates among younger patients (StCharles et 
al., 2009; Jabbour et al., 2012b), while others address 
that adherence is significantly lower among patients with 
advanced age, which often deal with chronic diseases, 
present decreased physical and cognitive activities and are 
more susceptible to complex treatment regimen due to the 
disease (Townsley et al.; 2005; Russo et al., 2013; Matikas 
et al., 2015). In relation to the stage of the disease, two 
studies included patients in blast crisis, four in accelerated 
phase and all studies evaluated the drug therapy in patients 
in the chronic phase of the disease (Table I). 
The analyzed articles were conducted in developed 
or developing countries. However, even considering 
only studies performed in developed countries with 
similar socioeconomic characteristics, it was observed 
heterogeneity among the rates of adherence and 
discontinuation ranging from 19.0 to 97.0% and from 1.8% 
to 41.0%, respectively. One reason for this heterogeneity 
may be related to the treatment period when the data 
collection was performed, since the patient adherence to 
the treatment at the beginning is higher (Reis et al., 2013). 
Evidences suggest that adherence to imatinib decreases 
throughout treatment period (Marin et al., 2010; Gater et 
al., 2012).
Among the selected studies, four were cross-
sectional, two were descriptive retrospective, four were 
longitudinal retrospective and four prospective studies. 
Regarding the longitudinal prospective, two were 
clinical study. Importantly, longitudinal studies provide 
answers related to the incidence of adherence and/or 
discontinuation of the drug prescribed during treatment 
(Ayres et al., 2014).
The indirect methods were used to evaluate 
adherence and/or discontinuation in the majority of 
the studies (n = 13), and questionnaire was the most 
employed instrument (n = 7). The analysis of medical 
records and Medication Possession Ratio (MPR) records 
was used in four studies and the evaluation of the hospital 
pharmacy database in one study. Both clinical studies 
have used imatinib plasma levels to assess adherence and/
or discontinuation. Furthermore, an association among 
different adherence methods was performed in four 
studies analyzed, Marin et al. (2010) used Medication 
Event Monitoring System (MEMS) combined with the 
drug detection in biological fluids, Noens et al. (2009) 
used structured questionnaire with manual tablets count, 
Eliasson et al. (2011) combined MEMS with questionnaire 
FIGURE 1 - Flowchart of the selected articles for the integrative 
review according to the criteria used in the study. 
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TABLE I - Analysis of published articles that evaluated the adherence and/or discontinuation of imatinib mesylate
Authors /year/
Study Center 
Coordinator 
(Country)
Number of 
patients
Age / Age range
Disease 
Stage
Follow-up 
period (days, 
months, years)
Study design
Method of 
adherence 
evaluation
Adherence 
(A) and/or 
Discontinuation 
(D)
Factors 
associated to 
poor adherence
Halpern et al. 
(2009), USA
374 (CML) 
465 (in total)
Mean 50.8 + 14,1 
years
CP
Minimum of 12 
months
Retrospective 
Cohort
MPR A: 70.1% -------
Noens et al. 
(2009), Spain
169 17-86 years AP / CP 90 days
Prospective 
Observational
Structured 
questionnaire/ 
Manual tablet 
count
A: 67.3% 
D: 1.8%
H i g h e r  a g e , 
male sex, longer 
time since CML 
diagnosis, living 
alone, imatinib 
dose > 600 mg/
day
Marin et al. 
(2010), UK
87 25.5-89 years CP 91 days Clinical study
MEMS/Imatinib 
plasma levels
A: 74%
Younger patients, 
ADR, Imatinib 
Dose > 400 mg/
day
Eliasson et al. 
(2011), UK 
21 26-70 years CP ------ Cross-sectional
MEMS/
Questionnaire
A: 19%
Forget t ing ,  no 
imatinib available 
a t  p h a r m a c y , 
ADR, travelling, 
s o c i a l i s i n g /
drinking alcohol
Efficace et al. 
(2012), USA
413 20-87 years CP ------ Cross-sectional
Structured 
questionnaire 
A: 53%
M e n t a l  h e a l t h 
d y s f u n c t i o n , 
lower  l eve l  o f 
social support
Jönsson et al. 
(2012), Sweden
38 26-88 years CP 12 months
Prospective  
Cohort
Structured 
Questionnaire
A: 97%
L o w e r  l e v e l 
of information, 
difficult access to 
the treating clinic
Cid et al. (2013), 
Brazil
100 21-40 years AP/ BP/ CP -------
Retrospective 
Descriptive
MPR
A: 53%  
D: 17%
ADR/ Intolerance
Hirji et al. 
(2013), USA
303
Mean 51.5 + 13.6 
years
CP  ------- Cross-sectional
Online 
Questionnaire
A: 66%
CML treatment 
res t r ic t ions  or 
requirements
Reis et al. 
(2013), Brazil
100 13-77 years AP/ BP/ CP -------
Retrospective 
Descriptive
MPR
A: 53% 
D: 41%
Unavailability of 
the drug, ADR 
Rosa et al. 
(2013), Brazil
25 25-88 years CP 18 months
Retrospective 
Observational
Structured 
Questionnaire
A: 62.5%
H i g h e r  a g e , 
longer treatment, 
female sex, ADR 
Santoleri et al. 
(2013), Italy
63 14-88 years CP 39 months
Retrospective 
Observational
Hospital 
pharmacy 
database
A: 83% 
D: 10%
Significant ADR, 
p o o r  p a t i e n t 
involvement in 
treatment 
Chen et al. 
(2014), Taiwan
119
Mean 45.7 ± 16.9 
years
CP
Mean 3.9 ± 2.9 
years
Retrospective 
Cohort
MPR/Biological 
marker
A: 73.1% 
D: 38.6%
ADR, lower level 
o f  s o c i a l  a n d 
medical support, 
a c c e s s i b i l i t y 
p r o b l e m s , 
ineffectiveness
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e and Chen et al. (2014) combined MPR with a biological 
marker detection.
Considering the methods to evaluate adherence, 
it was evidenced that the adherence rates was lower in 
studies that used questionnaires as data collection source 
compared to other assessment methods (Noens et al., 
2009; Efficace et al., 2012; Hirji et al., 2013; Rosa et al., 
2013). Although the questionnaire allows the follow-up of 
a large number of individuals and it is a low-cost and fast 
strategy, it is a method subject to bias and may interfere 
with the measurement of adherence, overestimating or 
underestimating the current medication adherence rate 
(Bloch, Melo, Nogueira, 2008; Ben, Neumann, Mengue, 
2012; Pérez-Escamilla et al., 2015).
Additionally a high adherence rate was found in 
studies that used the association between direct and 
indirect methods (Marin et al., 2010; Chen et al., 2014). 
It is important to mention that MEMS is a very costly 
method and subject to sampling errors. Despite these 
disadvantages, it allows to estimate the frequency of daily 
intake and interval between doses. On the other hand, drug 
detection in biological fluids, although it is a method of 
high financial cost, which evaluates only the recent drug 
use, it can eliminate the interference of patient’s report in 
assessing adherence (Pérez-Escamilla et al., 2015). The 
differences found in adherence and/or discontinuation 
rates may be justified by the use of different instruments 
to estimate the incidence and/or prevalence of patient 
adherence and/or discontinuation (Wetzels et al., 2006).
Evidence shows that there is no ideal method for 
evaluating medication adherence. Each assessment tool 
has advantages and disadvantages that favor or limit their 
applicability (Pérez-Escamilla et al., 2015). A systematic 
review of over 6500 citations, with full review of 549 
articles published between 1967 and 2001, showed there 
is no effective approach to assess adherence and that most 
of the methods used to evaluate adherence in a context of 
chronic diseases are generally complicated, expensive, and 
not consistently successful (Jabbour et al., 2012a). Thus, 
the authors suggest the combination of methods to monitor 
medication adherence with the purpose of reducing biases 
and inherent limitations to each instrument.
Regardind the rates of adherence and discontinuation 
among patients with CML in all studies included in this 
review, there was a variation of 19.0 to 97.0% and 1.8 
to 41.0%, respectively. Among the 14 studies analyzed, 
seven referred only to adherence, one referred only to 
discontinuation, five assess adherence and discontinuation 
and one included only suboptimal adherers. It was 
evident that few studies have assessed the achievement of 
cytogenetic and molecular response, which are important 
parameters for analyzing the absence of Philadelphia 
chromosome, as well as reduced levels of BCL-ABL 
rearrangement (Marin et al., 2010; Cid et al., 2013; Reis 
et al., 2013). In addition, four studies showed adherence 
rates relatively low to imatinib, such as between 19.0 and 
53.0%. It has been shown in clinical trials that reduced 
adherence rates are associated with lower rates of CCR 
and CMR (Marin et al., 2010; Cid et al., 2013). In the 
clinical context, several factors may influence adherence 
to treatment regimens and these include not only those 
aspects of the treatment, but also patient characteristics 
(Partridge et al., 2002; Efficace et al., 2012).
Factors related to poor adherence such as adverse 
drug reactions (ADRs) and unavailability of drugs were 
seen as major causes for discontinuation and/or non-
adherence to imatinib. Nine studies analyzed showed that 
adverse reactions to imatinib were related to non-adherence 
and/or intentional discontinuation. Drug unavailability was 
a factor related to discontinuation and/or non-adherence 
in three studies. Low social support, advanced age, poor 
access to health care, low level of information, prolonged 
treatment and high daily doses are other examples of factors 
associated to discontinuation and/or non-adherence. 
Authors /year/
Study Center 
Coordinator 
(Country)
Number of 
patients
Age / Age range
Disease 
Stage
Follow-up 
period (days, 
months, years)
Study design
Method of 
adherence 
evaluation
Adherence 
(A) and/or 
Discontinuation 
(D)
Factors 
associated to 
poor adherence
Efficace et al. 
(2014), Italy
175 20-87 years CP ------- Cross-sectional
Structured 
Questionnaire
A: Not assessed*
ADR, older age, 
male sex
Gotta et al. 
(2014), Italy
56 44-73 years AP / CP 13 months Clinical study
Drug detection in 
biological fluids
D: 23%
ADR/Intolerance, 
failure* 
MPR – Medication Possession Ratio; ADR – Adverse Drug Reaction; MEMS – Microelectronic Monitoring System; CP – Chronic Phase; AP – Accelerated 
Phase; BP – Blastic Phase. *In this study, only suboptimal adherers were included and classified based on their stated reasons for not adhering exactly as 
prescribed by their physicians.
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The ADRs are expected and explained by the the 
mechanism of action of the drug and can be correlated with 
changes in the drug dosage (Eliasson et al., 2011; Efficace 
et al., 2012; Rosa et al., 2013; Chen et al., 2014; Gotta et 
al., 2014). This was evidenced in two studies included in 
this work that showed that patients who took an increased 
dosage of imatinib had significantly lower adherence than 
patients who remained taking lower doses (Noens et al., 
2009; Marin et al., 2010). These dosage changes may 
affect therapeutic results, since rising the dose can increase 
the incidence of ADR, thereby lowering the adherence to 
the treatment over time (Chen et al., 2014).
Studies conducted in the USA show that non-
adherence to treatment may be associated with high 
healthcare costs, since it decreases the effectiveness of 
the treatment and requires a prolonged treatment period 
culminating in increased costs to the healthcare system 
(Reinhardt, Hussey, Anderson, 2004; Halpern et al., 2009). 
Another important aspect related to the non-adherence 
and/or discontinuation to be considered is relative to 
the availability of medicines in developing countries. 
The unstructured healthcare systems and failures in 
pharmaceutical care policies of the developing countries 
impair the access to medicines and can contribute to 
non-intentional discontinuation of the treatment by the 
patients. Studies performed in Brazil showed that less than 
half of people who have prescription drugs in the public 
healthcare system have access to all of them (Boing et al., 
2013) and the most frequent reason for non-adherence 
is the unavailability of the drug at the healthcare system 
(Reis et al., 2013). Moreover, studies show that the lack of 
access to medicines can generate not only a direct impact 
on clinical, social and economic conditions of the patient, 
but also an increase in spending on secondary and tertiary 
care (Reis, Perini, 2008). 
Knowing the current rates of adherence and/
or discontinuation is essential to develop strategies to 
improve pharmacotherapeutic results. Thus, it is worth 
noting that the follow-up of patients that take oral 
medication for CML plays a key role in promoting and 
improving adherence to treatment and also to identify, 
prevent and solve other drug related problems. Well-
trained pharmacists can solve those problems through 
interventions such as medication management, providing 
information and guidance that improve adherence to drug 
therapy and that increase the effectiveness and medication 
safety (Partridge et al., 2002; Weingart et al., 2008). 
CONCLUSION
In this study, we observed diverse rates of adherence 
and/or discontinuation of imatinib, ranging from 19.0 to 
97.0% and from 1.8 and 41.0%, respectively. This can 
be due to the use of various tools to access adherence, 
different treatment period when data collection of the 
studies was conducted and by socioeconomic differences 
among countries, health systems, age range and changes in 
dosage. Few studies evaluated cytogenetic and molecular 
responses to imatinib treatment being necessary further 
efforts of the clinical research community in this aspect. 
Besides that, there is a lack of studies of the predictors for 
adherence and/or discontinuation of imatinib. Therefore, 
health professionals should also be able to identify 
predictors of poor adherence to imatinib,which allows 
them to seek for strategies that improves adherence and 
consequently leads to better clinical outcomes. Therefore, 
this study showed that patient education combined with a 
follow-up by pharmacists or other health professionals can 
maximize patient adherence and minimize discontinuation 
of pharmacotherapy.
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